Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937592

SCHEMBL2937592

SCHEMBL2937592

COc1ccc(N(C)C(=O)c2cnccc2CN2C(=O)N(c3ccc(SC(F)(F)F)cc3)C(=O)C2C)cc1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ORAI1 Q96D31 1/20 0.37
▸ IGF1R P08069 6/20 0.37
▸ TP53 P04637 2/20 0.35
▸ TSHR P16473 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ GAA P10253 2/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ HCRTR1 O43613 1/20 0.33
▸ HCRTR2 O43614 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ MAPT P10636 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934282 0.91 SMO (0.41) IGF1RKMT2A
SCHEMBL2932989 0.91 IGF1R (0.42) IGF1RKMT2A
SCHEMBL2941293 0.90 ORAI1 (0.39) ORAI1IGF1RTP53TSHRPOLB
SCHEMBL2940863 0.87 IGF1R (0.53) ORAI1IGF1RTP53TSHRPOLB
SCHEMBL2938406 0.87 IGF1R (0.42) IGF1R
SCHEMBL2937595 0.84 IGF1R (0.44) IGF1RTP53TSHRPOLBMAPK1
SCHEMBL2935992 0.84 IGF1R (0.37) ORAI1IGF1RTP53GAAALDH1A1
SCHEMBL2938486 0.84 IGF1R (0.43) IGF1RHCRTR1HCRTR2
SCHEMBL2938680 0.83 IGF1R (0.55) IGF1R
SCHEMBL2936267 0.83 SMO (0.41) ORAI1IGF1RKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 — — EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 ORAI1 3681/4885IGF1R 1595/4885TP53 490/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA ORAI1 3683/4885IGF1R 962/4885TP53 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.